Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 6 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Operating profit fell short of plan due to deteriorating manufacturing costs in North America and Europe for the Automotive segment, rising raw material and fuel prices in Southeast Asia for Essential Chemicals, and sales volumes falling short of plan in Europe and Asia for the Architectural Glass segment and in the biopharmaceutical CDMO business of the Life Science segment, among other factors. In addition, a loss on disposal of fixed assets, which had not been anticipated initially, was recorded in connection with the sale of the biopharmaceutical CDMO site in Colorado, US.
Loss on disposal of fixed assets (in connection with the sale of the biopharmaceutical CDMO site in Colorado, US; amount: Not disclosed)
| Item | Details |
|---|---|
| Net Sales | 2,200,000 Millions of yen → 2,200,000 Millions of yen |
| Operating profit | 150,000 Millions of yen → 120,000 Millions of yen（-20.0%） |
| Profit attributable to owners of the parent | 77,000 Millions of yen → 40,000 Millions of yen（-48.1%） |
| Net income per share | 363.12 Yen → 188.55 Yen（-48.1%） |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 6 February 2026 |
| Previous-period results | Revenue ¥2,058.832 billion, operating profit ¥127.465 billion, profit before tax ¥124.758 billion, net income ¥79.470 billion, net income attributable to owners of the parent ¥69.162 billion, basic earnings per share ¥326.20 |
| Reason for the revision | Operating profit fell short of plan due to deteriorating manufacturing costs in North America and Europe for the Automotive segment, rising raw material and fuel prices in Southeast Asia for Essential Chemicals, and sales volumes falling short of plan in Europe and Asia for the Architectural Glass segment and in the biopharmaceutical CDMO business of the Life Science segment, among other factors. In addition, a loss on disposal of fixed assets, which had not been anticipated initially, was recorded in connection with the sale of the biopharmaceutical CDMO site in Colorado, US. |
| Details and amount of extraordinary loss | Loss on disposal of fixed assets (in connection with the sale of the biopharmaceutical CDMO site in Colorado, US; amount: Not disclosed) |
| Dividend forecast revision | No revision |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Manufacturing costs deteriorated in North America and Europe for Automotive, raw material and fuel prices rose in Southeast Asia for Essential Chemicals, and sales volumes fell short of plan in Europe and Asia for Architectural Glass and in the biopharmaceutical CDMO business of Life Science. In addition, a loss on disposal of fixed assets will be recorded in connection with the sale of the biopharmaceutical CDMO site in Colorado, US.